PRESS RELEASE published on 05/23/2024 at 14:30, 3 months 28 days ago Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology (ASCO) Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Product Jaguar Health, Inc. announces commercial launch at ASCO Annual Meeting for Gelclair, FDA-approved oral mucositis product. Focus on cancer supportive care with phase 3 OnTarget trial results impending Jaguar Health Phase 3 Trial Gelclair Oral Mucositis ASCO Annual Meeting
BRIEF published on 05/17/2024 at 22:20, 4 months 3 days ago Jaguar Health, Inc. annonce un regroupement d'actions Investisseurs Institutionnels Conformité NASDAQ Ajustement Des Stocks Regroupement Inversé Des Actions Jaguar Santé Inc.
BRIEF published on 05/17/2024 at 22:20, 4 months 3 days ago Jaguar Health, Inc. Announces Reverse Stock Split Jaguar Health Inc Reverse Stock Split Nasdaq Compliance Institutional Investors Stock Adjustment
PRESS RELEASE published on 05/17/2024 at 22:15, 4 months 3 days ago Jaguar Health, Inc. Announces Reverse Stock Split Jaguar Health announces reverse split approval at Special Meeting of Stockholders to boost Nasdaq compliance. Stock trading on split-adjusted basis from May 23, 2024. Details in SEC filing Stockholders Meeting Jaguar Health Nasdaq Compliance Reverse Split SEC Filing
BRIEF published on 05/14/2024 at 14:05, 4 months 6 days ago Jaguar Health publie ses résultats financiers du premier trimestre 2024 Résultats Financiers Crofelemer Santé Jaguar T1 2024 Gelclair
BRIEF published on 05/14/2024 at 14:05, 4 months 6 days ago Jaguar Health Reports First Quarter 2024 Financial Results Financial Results Crofelemer Jaguar Health Q1 2024 Gelclair
PRESS RELEASE published on 05/14/2024 at 14:00, 4 months 6 days ago Jaguar Health Reports First Quarter 2024 Financial Results Jaguar Health, Inc. reports Q1 2024 financial results, with revenue increasing 20% over Q1 2023. Key updates include OnTarget trial progress and Gelclair® commercial launch plans Financial Results Jaguar Health Q1 2024 OnTarget Trial Gelclair
BRIEF published on 05/13/2024 at 18:40, 4 months 7 days ago Jaguar Health, Inc. annonce une webdiffusion du premier trimestre 2024 pour discuter des données financières et des mises à jour de l'entreprise Rapport Sur Les Revenus Santé Jaguar T1 2024 Webdiffusion Financière Mises À Jour De L'entreprise
BRIEF published on 05/13/2024 at 18:40, 4 months 7 days ago Jaguar Health, Inc. Announces Q1 2024 Webcast to Discuss Financials and Corporate Updates Earnings Report Jaguar Health Q1 2024 Financial Webcast Corporate Updates
PRESS RELEASE published on 05/13/2024 at 18:35, 4 months 7 days ago REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates Jaguar Health, Inc. to conduct investor webcast on May 14, 2024 at 8:30 a.m. Eastern to review first-quarter 2024 financials and provide corporate updates. Company plans to file its Earnings Report on the same day Investor Webcast Form 10-Q Jaguar Health Inc. Corporate Updates First-quarter Financials
Published on 09/20/2024 at 23:40, 5 hours 7 minutes ago Integrated BioPharma Reports Results for Its Quarter and Fiscal Year Ended June 30, 2024
Published on 09/20/2024 at 23:30, 5 hours 17 minutes ago Final Bell Holdings International Ltd. Announces Sale of Final Bell Corp.
Published on 09/20/2024 at 23:00, 5 hours 47 minutes ago AI/ML Innovations Inc. Provides Second Status Update
Published on 09/20/2024 at 22:30, 6 hours 17 minutes ago Electric Metals Announces Changes to its Board of Directors
Published on 09/20/2024 at 22:15, 6 hours 32 minutes ago Torq Clarifies Finder’s Warrant Exercise Price of $0.10 Financing
Published on 09/20/2024 at 22:58, 5 hours 49 minutes ago Freelance.com: Mise à disposition du Document d’Enregistrement Universel 2023
Published on 09/20/2024 at 21:00, 7 hours 47 minutes ago Aurubis celebrates ribbon-cutting at the first multimetal recycling plant in the United States
Published on 09/20/2024 at 20:14, 8 hours 32 minutes ago EQS-Adhoc: GRAMMER AG sells TMD Group in North America
Published on 09/20/2024 at 19:50, 8 hours 57 minutes ago BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator
Published on 09/20/2024 at 19:47, 9 hours ago EQS-Adhoc: BRAIN Biotech AG concludes royalty monetization deal for up to EUR 128.88 million on investigational pharma compound deucrictibant with Royalty Pharma
Published on 09/20/2024 at 17:40, 11 hours 7 minutes ago Availability of the 2024 Half-Year Financial Report
Published on 09/20/2024 at 17:40, 11 hours 7 minutes ago Mise à disposition du Rapport Financier Semestriel 2024